Alexandre Nunes

Mr. Alexandre Nunes

Institute of Biomedicine—iBiMED, Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
ANAlexandre Nunes
Alexandre Nunes
DRDiana Roberta Ribeiro
Diana Roberta Ribeiro
MMMariana Marques
Mariana Marques
MSManuel A.S. Santos
Manuel A.S. Santos
DRDaniela Ribeiro
Daniela Ribeiro
ASAna Soares
Ana Soares

13 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AFAna Rita Ferreira
Ana Rita Ferreira
BRBruno Ramos
Bruno Ramos
ANAlexandre Nunes
Alexandre Nunes
DRDaniela Ribeiro
Daniela Ribeiro
Hepatitis C virus (HCV) infections constitute a major public health problem and are the main cause of chronic hepatitis and liver disease worldwide. The existing drugs, while effective, are expensive and associated with undesirable secondary effects. There is, hence, an urgent need to develop novel therapeutics, as well as an effective vaccine to prevent HCV infection. Understanding the interplay between HCV and the host cells will certainly contribute to better comprehend disease progression and may unravel possible new cellular targets for the development of novel antiviral therapeutics. Here, we review and discuss the interplay between HCV and the host cell innate immunity. We focus on the different cellular pathways that respond to, and counteract, HCV infection and highlight the evasion strategies developed by the virus to escape this intracellular response.

22 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DRDiana Ribeiro
Diana Ribeiro
ANAlexandre Nunes
Alexandre Nunes
MMMie Monti
Mie Monti
LLLaia Llovera
Laia Llovera
MBMaximilian Berg
Maximilian Berg
ASAna Soares
Ana Soares
Influenza A virus (IAV), as all other viruses, is completely dependent on the host translation machinery components, including host transfer RNAs (tRNAs), to effectively decode its genome. However, while the human genome is biased towards cytosine (C) and guanosine (G)-ending codons, the IAV genome is skewed towards adenine (A) and uridine (U)-ending codons. Nevertheless, translation of IAV’s RNA genome is highly efficient. Here we show that host tRNA and tRNA epitranscriptome dynamics are important regulators of IAV RNA translation and host antiviral responses. We show that the levels of several tRNA modifications, including 5-methylcarboxymethyluridine (mcm 5 U 34 ) and 5-methoxycarbonylmethyl-2-thiouridine (mcm 5 s 2 U 34 ), and their cognate writers, vary over the course of IAV infection. Additionally, we demonstrate that a set of tRNAs are preferentially recruited to ribosomes upon IAV infection, in line with IAV codon usage requirements. We further show that loss of ELP3, the catalytic subunit of the elongator complex, which is involved in the catalysis of mcm 5 U 34 and of mcm 5 s 2 U 34 , induces tRNA hypomodifications, impairs translation of codon biased IAV genes and triggers the integrated stress response (ISR), interfering with IAV propagation. Taken together, our results uncover the relevance of host tRNAs and their modifications for optimal expression of viral genomes and host antiviral responses, setting the tRNA epitranscriptome as a promising target for the development of host-based antiviral therapies.